Federal Register / Vol. 83, No. 10 / Tuesday, January 16, 2018 / Notices 2167 

If you need special accommodations 

due to a disability, please contact Susan 

Monahan, Center for Devices and 

Radiological Health, Food and Drug 

Administration, 10903 New Hampshire 

Ave., Bldg. 32, Rm. 5231, Silver Spring, 

MD 20993–0002, 301–796–5661, or 

email: Susan.Monahan@fda.hhs.gov, no 

later than May 8, 2018. 

Requests for Oral Presentations: 

During online registration you may 

indicate if you wish to present during a 

public comment session or participate 

in a specific session, and which topic(s) 

you wish to address. We will do our 

best to accommodate requests to make 

public comments. Individuals and 

organizations with common interests are 

urged to consolidate or coordinate their 

presentations, and request time for a 

joint presentation, or submit requests for 

designated representatives to participate 

in the focused sessions. Following the 

close of registration, we will determine 

the amount of time allotted to each 

presenter and the approximate time 

each oral presentation is to begin, and 

will select and notify participants by 

May 16, 2018, midnight Eastern Time. 

All requests to make oral presentations 

must be received by the close of 

registration on May 14, 2018, 4 p.m. 

Eastern Time. If selected for 

presentation, any presentation materials 

must be emailed to Scott Colburn (see 

FOR FURTHER INFORMATION CONTACT) no 

later than May 18, 2018, midnight 

Eastern Time. No commercial or 

promotional material will be permitted 

to be presented or distributed at the 

public workshop. 

Streaming Webcast of the Public 

Workshop: This public workshop will 

also be webcast. The webcast link will 

be available on the registration web page 

after May 14, 2018. Please visit FDA’s 

Medical Devices News & Events— 

Workshops & Conferences calendar 

(https://www.fda.gov/MedicalDevices/ 

NewsEvents/WorkshopsConferences/ 

default.htm) and select this event from 

the list of items provided. Organizations 

are requested to register all participants, 

but to view using one connection per 

location. 

If you have never attended a Connect 

Pro event before, test your connection at 

https://collaboration.fda.gov/common/ 

help/en/support/meeting_test.htm. To 

get a quick overview of the Connect Pro 

program, visit https://www.adobe.com/ 

go/connectpro_overview. FDA has 

verified the website addresses in this 

document, as of the date this document 

publishes in the Federal Register, but 

websites are subject to change over time. 

Transcripts: Please be advised that as 

soon as a transcript of the public 

workshop is available, it will be 

accessible at https://

www.regulations.gov. It may be viewed 

at the Dockets Management Staff (see 

ADDRESSES). A link to the transcript will 

also be available on the internet at 

https://www.fda.gov/MedicalDevices/ 

NewsEvents/WorkshopsConferences/ 

default.htm. 

Dated: January 9, 2018. 

Leslie Kux, 

Associate Commissioner for Policy. 

[FR Doc. 2018–00551 Filed 1–12–18; 8:45 am] 

BILLING CODE 4164–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Advisory Council on Alzheimer’s 

Research, Care, and Services; Meeting 

AGENCY: Assistant Secretary for 

Planning and Evaluation, HHS. 

ACTION: Notice of meeting. 

SUMMARY: This notice announces the 

public meeting of the Advisory Council 

on Alzheimer’s Research, Care, and 

Services (Advisory Council). The 

Advisory Council on Alzheimer’s 

Research, Care, and Services provides 

advice on how to prevent or reduce the 

burden of Alzheimer’s disease and 

related dementias on people with the 

disease and their caregivers. During the 

January meeting, the Research 

Subcommittee will be taking charge of 

the theme, focusing on the process from 

targets to treatments. The Council will 

hear speakers on the preclinical 

pipeline, the clinical trial pipeline, and 

the industry perspective. The meeting 

will also include discussion of a driver 

diagram to guide the Council’s future 

work, updates and a report from the 

October Care Summit, and federal 

workgroup updates. 

DATES: The meeting will be held on 

January 26, 2018 from 9:00 a.m. to 5:00 

p.m. EDT. 

ADDRESSES: The meeting will be held in 

Room 800 in the Hubert H. Humphrey 

Building, 200 Independence Avenue 

SW, Washington, DC 20201. 

Comments: Time is allocated in the 

afternoon on the agenda to hear public 

comments. The time for oral comments 

will be limited to two (2) minutes per 

individual. In lieu of oral comments, 

formal written comments may be 

submitted for the record to Rohini 

Khillan, OASPE, 200 Independence 

Avenue SW, Room 424E, Washington, 

DC 20201. Comments may also be sent 

to napa@hhs.gov. Those submitting 

written comments should identify 

themselves and any relevant 

organizational affiliations. 

FOR FURTHER INFORMATION CONTACT: 

Rohini Khillan (202) 690–5932, 

rohini.khillan@hhs.gov. Note: Seating 

may be limited. Those wishing to attend 

the meeting must send an email to 

napa@hhs.gov and put ‘‘January 26 

Meeting Attendance’’ in the Subject line 

by Tuesday, January 16, so that their 

names may be put on a list of expected 

attendees and forwarded to the security 

officers at the Department of Health and 

Human Services. Any interested 

member of the public who is a non-U.S. 

citizen should include this information 

at the time of registration to ensure that 

the appropriate security procedure to 

gain entry to the building is carried out. 

Although the meeting is open to the 

public, procedures governing security 

and the entrance to Federal buildings 

may change without notice. If you wish 

to make a public comment, you must 

note that within your email. 

SUPPLEMENTARY INFORMATION: Notice of 

these meetings is given under the 

Federal Advisory Committee Act (5 

U.S.C. App. 2, section 10(a)(1) and 

(a)(2)). Topics of the Meeting: During 

the January meeting, the Research 

Subcommittee will be taking charge of 

the theme, focusing on the process from 

targets to treatments. The Council will 

hear speakers on the preclinical 

pipeline, the clinical trial pipeline, and 

the industry perspective. The meeting 

will also include discussion of a driver 

diagram to guide the Council’s future 

work, updates and a report from the 

October Care Summit, and federal 

workgroup updates. 

Procedure and Agenda: This meeting 

is open to the public. Please allow 30 

minutes to go through security and walk 

to the meeting room. The meeting will 

also be webcast at www.hhs.gov/live. 

Authority: 42 U.S.C. 11225; Section 2(e)(3) 

of the National Alzheimer’s Project Act. The 

panel is governed by provisions of Public 

Law 92–463, as amended (5 U.S.C. Appendix 

2), which sets forth standards for the 

formation and use of advisory committees. 

Dated: January 9, 2018. 

John R. Graham, 

Acting Assistant Secretary for Planning and 

Evaluation. 

[FR Doc. 2018–00480 Filed 1–12–18; 8:45 am] 

BILLING CODE 4150–05–P 


daltland on DSKBBV9HB2PROD with NOTICES